论文部分内容阅读
美国FDA于2011年2月4日通过快速审批程序批准Makena(己酸羟孕酮,hydroxyprogesterone caproate)用于有早产病史的孕妇预防早产,但不适用于怀有双胞胎或多胞胎的孕妇。
The FDA approved Makena (hydroxyprogesterone caproate) through a rapid approval process on February 4, 2011 for the prevention of preterm birth in pregnant women with a history of preterm birth but not in pregnant women with twin or multiple births.